scholarly journals Healthcare resource utilization after initiation of sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors or other glucose‐lowering drugs in Japanese patients with type 2 diabetes

2021 ◽  
Vol 23 (S2) ◽  
pp. 28-39
Author(s):  
Shun Kohsaka ◽  
Masayoshi Takeda ◽  
Yoko Kidani ◽  
Toshitaka Yajima
Keyword(s):  
Type 2 Diabetes ◽  
Resource Utilization ◽  
Healthcare Resource ◽  
Japanese Patients ◽  
Dipeptidyl Peptidase ◽  
Healthcare Resource Utilization ◽  
Glucose Lowering ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors

The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes

Metabolism ◽  
2020 ◽  
Vol 109 ◽  
pp. 154295
Author(s):  
Anca Pantea Stoian ◽  
Alexandros Sachinidis ◽  
Roxana Adriana Stoica ◽  
Dragana Nikolic ◽  
Angelo Maria Patti ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Dipeptidyl Peptidase ◽  
Oral Glucose ◽  
Efficacy And Safety ◽  
Glucose Lowering ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors

scholarly journals Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study

2014 ◽  
Vol 51 (6) ◽  
pp. 1015-1023 ◽  
Author(s):  
Seoyoung C. Kim ◽  
Robert J. Glynn ◽  
Jun Liu ◽  
Brendan M. Everett ◽  
Allison B. Goldfine
Keyword(s):  
Type 2 Diabetes ◽  
Cohort Study ◽  
Cardiovascular Events ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors
Sign in / Sign up

Export Citation Format

Share Document